Article
Hematology
Kitsada Wudhikarn, Amber C. King, Mark B. Geyer, Mikhail Roshal, Yvette Bernal, Boglarka Gyurkocza, Miguel-Angel Perales, Jae H. Park
Summary: This study reports the outcomes of B-ALL patients previously treated with blinatumomab and inotuzumab. Inotuzumab induced complete remission in most patients who relapsed after blinatumomab treatment. While a switch in therapy was beneficial for some patients, the relapse rate remains high.
Article
Hematology
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Summary: Autologous stem cell transplantation (ASCT) following anti-PD-1 therapy shows promising outcomes for relapsed/refractory Hodgkin lymphoma (HL) patients, even in high-risk cases, with favorable survival rates observed.
Article
Oncology
Guan-Hua Hu, Xiang-Yu Zhao, Ying-Xi Zuo, Ying-Jun Chang, Pan Suo, Jun Wu, Yue-Ping Jia, Ai-Dong Lu, Ying-Chun Li, Yu Wang, Shun-Chang Jiao, Long-Ji Zhang, Jun Kong, Chen-Hua Yan, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Yi-Fei Cheng, Yu Wang, Le-Ping Zhang, Xiao-Jun Huang
Summary: The study assessed the efficacy and safety of bridging CAR-T therapy to Haplo-HSCT and found that Haplo-HSCT may be a safe and effective treatment strategy to improve event-free survival and overall survival after CAR-T therapy.
Review
Oncology
Jonathan A. Webster, Leo Luznik, Ivana Gojo
Summary: Advances in allo-HCT have shifted the primary cause of treatment failure for AML patients from transplant-related mortality to disease relapse. Post-transplant relapsed AML presents a clinical challenge due to transplant-related toxicities increasing the risk of treatment-related morbidity and mortality.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Eva A. S. Koster, Edouard F. Bonneville, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Danielle van Lammeren, Hendrik Veelken, Hein Putter, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede
Summary: Alloreactive donor-derived T-cells play a crucial role in alloimmune responses after allogeneic hematopoietic stem cell transplantation (alloSCT), affecting both the prevention of leukemia relapse and the risk of graft-versus-host disease (GvHD). This study investigates the complex associations between T-cell kinetics and alloimmune responses in acute leukemia patients receiving alemtuzumab-based T-cell depletion alloSCT. The results demonstrate that donor lymphocyte infusion (DLI) can lead to detectable T-cell expansion, with CD4+ T-cells showing the strongest association with the development of alloimmune responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Jinhua Ren, QiaoXian Lin, Qi Chen, Jingjing Xu, Dabin Chen, Renli Chen, Kangni Lin, Haojie Zhu, Chenjing Ye, Xiaofeng Luo, Shaozhen Chen, Hui Kong, Qiong Lin, Nan Li, Xu Lin, Zhizhe Chen, Jianda Hu, Ting Yang
Summary: Adoptive transfer of HBV immunity was investigated in 112 patients without HBsAb at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA and HBsAg cleared in HBsAg+ patients, while all HBsAg- patients acquired HBsAb immediately. However, HBsAb subsequently declined, with 58.2% of patients losing HBsAb during follow-up. Multivariate analysis suggested that lack of CMV clearance, aGVHD, and no HBsAb loss were independent risk factors for overall survival. Overall, adoptive immune transfer provides anti-HBV protection, and HBsAb loss after allo-HSCT predicts better survival.
Letter
Oncology
Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Wei Cui, Baoquan Song, Jia Yin, Zheng Li, Xiaming Zhu, Changju Qu, Tianhui Liu, Wenhong Shen, Mingqing Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Summary: The study demonstrated the potential efficacy and safety of CD38-targeted CAR-T cells in treating relapsed AML patients by eliminating CD38 positive blasts without off-target effects, although the risk of relapse still exists.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Hui Liu, Li Xuan, Ren Lin, Lan Deng, Zhiping Fan, Danian Nie, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, Jieyu Ye, Hua Jin, Dongjun Lin, Liping Ma, Jing Sun, Fen Huang, Qifa Liu
Summary: The study suggests that a preemptive TKIs strategy based on BCR/ABL molecular monitoring may reduce relapse and improve survival in Ph+ALL patients undergoing allo-HCT.
Article
Immunology
Ying Han, Hao Yao, Guang-cui He, Si-han Lai, Yan Deng, Shan Zhang, Ying He, Yi-song Xiong, Alex H. Chang, Yi Su, Hai Yi
Summary: Demethylating drugs combined with CD7-targeted CAR-T cell therapy is a feasible treatment option for patients with mixed phenotype acute leukemia (MPAL) who experience relapse after transplantation, showing good efficacy and safety. This case report provides preliminary evidence for a long-lasting complete remission and better prognosis with CD7-targeted CAR-T cell therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Gerard Socie
Summary: The Oncology Grand Rounds series aims to help doctors better apply clinical research to actual patient treatment. This particular round focused on the management and complications of hematopoietic stem-cell transplantation (HSCT) in acute myelogenous leukemia (AML). The study found that while transplantation therapy provides long-term survival opportunities, it also increases the risk of late complications.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Kaito Harada, Shohei Mizuno, Shingo Yano, Akiyoshi Takami, Hiroto Ishii, Kazuhiro Ikegame, Yuho Najima, Shinichi Kako, Takashi Ashida, Souichi Shiratori, Shuichi Ota, Makoto Onizuka, Kentaro Fukushima, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. Our retrospective analysis showed that a higher CD3(+) cell count was associated with an increased risk of acute GVHD, and preemptive DLI resulted in better overall response.
ANNALS OF HEMATOLOGY
(2022)
Article
Immunology
Yutong Tang, Zhenyang Zhou, Han Yan, Yong You
Summary: In this study, a case of AML patient with RUNX1-RUNX1T1 was reported, who underwent preemptive treatment with the combined application of tislelizumab and azacitidine to prevent post-transplant relapse. After the combination therapy, the patient achieved complete remission with improved hematologic response, but also experienced immune-related adverse events which were well controlled by immunosuppressive therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Yingying Li, Yixue Li, Mingming Zhang, Houli Zhao, Miaoyong Zhu, He Huang, Yongxian Hu
Summary: This study investigated the effectiveness of donor-derived chimeric antigen receptor T (CAR-T) cells in treating relapsed cases after allo-HSCT, and the therapeutic effect of donor-derived PBSCs on pancytopenia after CAR-T cell therapy. The results showed that donor-derived CAR-T cell therapy was safe and effective in relapsed/refractory ALL patients after allo-HSCT. Donor-derived PBSCs infusion could achieve hematopoietic recovery with controllable aGVHD in patients with persistent pancytopenia.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.